Here, through comprehensive characterisation of genomic alterations and T cell fraction in pre-treatment tumour biopsies along with annotated clinicopathological characteristics we identified a subset of these features which may be associated with response to neoadjuvant therapy for HER2+ breast cancer patients. This evidence concerns the gene ERBB2 and neoplasm.